Search

Your search keyword '"Kastelein, John J.P."' showing total 420 results

Search Constraints

Start Over You searched for: Author "Kastelein, John J.P." Remove constraint Author: "Kastelein, John J.P." Database Unpaywall Remove constraint Database: Unpaywall
420 results on '"Kastelein, John J.P."'

Search Results

2. Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects: Results from a Randomized Phase 2 Trial

3. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

8. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

9. PEGOZAFERMIN PROVIDES BENEFICIAL LIPID EFFECTS IN SUBJECTS WITH SEVERE HYPERTRIGLYCERIDEMIA REGARDLESS OF BACKGROUND LIPID MODIFYING THERAPY STATUS: AN ANALYSIS OF THE PHASE 2 ENTRIGUE STUDY

13. Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia

14. Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study

20. EVOLOCUMAB IN PEDIATRIC HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: RESULTS FROM THE HAUSER OPEN-LABEL EXTENSION STUDY

22. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

23. Contributors

26. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial

28. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

29. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction

30. Familial Dyslipidaemia in Children

31. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia

32. Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial

33. Corrigendum to “Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia” J Clin Lipidol 11 (2017) 1338-1346

34. Evinacumab for Homozygous Familial Hypercholesterolemia

35. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia

37. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

38. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia

43. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies

44. Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses

46. Mendelian Randomization Study of ACLY and Cardiovascular Disease

47. Moving Targets

48. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction

Catalog

Books, media, physical & digital resources